The Legacy Partner Society is an exclusive group of donors who have committed a bequest to the AAPP Foundation. These gifts allow the Foundation to plan for the future, working towards a world where individuals with mental health disorders receive optimal care because psychiatric pharmacists are an essential member of the health care team.
No summary available
Toolkit on Alcohol Use Disorder with quick tips and guideline summaries: Screening/Diagnosis, Alcohol Withdrawal, Maintenance Treatment of AUD, Special Populations and Treatment, Co-occurring Disorders, Harm Reduction Strategies, Resources and References.
As the philanthropic arm of the American Association of Psychiatric Pharmacists (AAPP), the AAPP Foundation's mission is to advance the psychiatric pharmacy profession by supporting clinical outcomes research, pharmacy practice innovation and expansion, and pharmacy workforce development. We offer various grant programs, sponsorships, and educational opportunities to advance psychiatric pharmacists, including four grant programs that are currently accepting applications.
No summary available
No summary available
No summary available
Drs. Catherine Smith, PharmD, BCPS, BCPP, and Kristin Helmboldt, PharmD, BCPP, share how systematic thinking, shared decision-making, and the acknowledgement of uncertainty can assist with clinical decision-making in evidence gaps.
Thanks for our incredibly generous donors, 33 students received registration grants to cover the full in-person fee for the AAPP 2026 Annual Meeting in Seattle, Washington! Please enjoy the thank you notes from grant recipients included in this article.
Devon A. Sherwood, PharmD, BCPP Associate Professor of Pharmacy Practice University of New England College of Pharmacy Portland, ME
This report presents data from the 2025 RAND Psychedelics Survey regarding the use of specific psychedelic substances and policy preferences among U.S. veterans.
Describes CPP independent B-MOUD prescribing within VHA as an effective practice that could model pharmacist care in other large health care systems.
This edition reflects the considerable growth of the evidence base since the publication of 2019 guidelines and expands the scope of guidance on dementia risk reduction.
Among hospitalized adult males with MUD, adjunctive mirtazapine significantly reduced craving over 8 weeks.
This guideline focuses on the identification, diagnosis, treatment, and promotion of recovery for patients with StUD, stimulant intoxication, and stimulant withdrawal.
In this study of buprenorphine-naloxone vs XR naltrexone, initiating buprenorphine-naloxone after MMOW discharge was associated with a lower risk of nonfatal opioid overdose at 24 weeks than initiating XR naltrexone, but a similar risk of all-cause mortality.
SMAs appear feasible and acceptable for addiction care and may support treatment retention and patient experience.
The widely varying experiences of people in the United States participating in mandated substance use disorder treatment programs underscore the difficulty of rendering sweeping conclusions about the benefits and harms of mandated treatment and highlight the need to calibrate programs and policies to meet the specific needs and interests of different groups facing mandates.
In this survey study, an appreciable portion of adolescents were not aware of the dangers of fentanyl use.
This systematic review and meta-analysis of VLNC RCTs found minimal evidence of compensation among people assigned to smoke VLNCs.
LA Times headlines have been tracking the broader rollout of contingency management, and there is genuine reason for optimism.
STAT’s investigation turned up numerous ways the nation can curb excessive drinking and its related harms.
Alcohol-related mortality has increased substantially over 55 years, with profound demographic shifts including a complete racial disparity inversion and narrowing gender gap.
This publication provides an overview of the Certified Community Behavioral Health Clinic (CCBHC) model, including its purpose, core service requirements, and impact on expanding access to comprehensive mental health and substance use disorder care.
AAPP’s newest policy requests provide support to rescheduling cannabis and psychedelics to reduce barriers to rigorous clinical research with the goal to strengthen the evidence base on both benefit and harm. Please visit these policy asks and use them as the basis for advocacy in your city, state, and federally.